NewAmsterdam Pharma Company NVNASDAQ:NAMS
- LAST PRICE18.9500
- TODAY'S CHANGE (%)0.9200 (5.1026%)
- Bid / Lots18.9000/ 8
- Ask / Lots19.0000/ 7
- Open / Previous Close17.9300 / 18.0300
- Day Range
- 52 Week Range
- Volume85,710
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NAMS |
|---|---|---|
| 09:32 ET | 1917 | 17.93 |
| 09:33 ET | 100 | 17.9 |
| 09:37 ET | 929 | 17.7 |
| 09:39 ET | 100 | 17.63 |
| 09:44 ET | 200 | 17.61 |
| 09:48 ET | 100 | 17.64 |
| 09:51 ET | 200 | 17.61 |
| 09:53 ET | 200 | 17.965 |
| 09:57 ET | 500 | 17.825 |
| 10:02 ET | 900 | 18.065 |
| 10:08 ET | 400 | 18.16 |
| 10:22 ET | 100 | 18.185 |
| 10:24 ET | 1664 | 18.26 |
| 10:27 ET | 150 | 18.1797 |
| 10:31 ET | 200 | 18.175 |
| 10:33 ET | 200 | 18.24 |
| 10:40 ET | 2995 | 18.02 |
| 10:42 ET | 100 | 18.03 |
| 10:44 ET | 500 | 18.14 |
| 10:45 ET | 100 | 18.18 |
| 10:47 ET | 1160 | 18.26 |
| 10:49 ET | 300 | 18.26 |
| 10:51 ET | 240 | 18.38 |
| 10:58 ET | 150 | 18.352 |
| 11:00 ET | 500 | 18.4 |
| 11:05 ET | 2479 | 18.315 |
| 11:07 ET | 100 | 18.305 |
| 11:12 ET | 126 | 18.37 |
| 11:20 ET | 100 | 18.305 |
| 11:23 ET | 100 | 18.3 |
| 11:30 ET | 1300 | 18.27 |
| 11:32 ET | 277 | 18.3 |
| 11:34 ET | 2900 | 18.5 |
| 11:43 ET | 100 | 18.42 |
| 11:48 ET | 400 | 18.42 |
| 11:52 ET | 100 | 18.415 |
| 11:54 ET | 1617 | 18.65 |
| 11:56 ET | 1750 | 18.55 |
| 11:57 ET | 100 | 18.55 |
| 12:01 ET | 100 | 18.55 |
| 12:08 ET | 100 | 18.55 |
| 12:12 ET | 100 | 18.545 |
| 12:15 ET | 200 | 18.63 |
| 12:17 ET | 100 | 18.63 |
| 12:19 ET | 200 | 18.555 |
| 12:24 ET | 100 | 18.5575 |
| 12:26 ET | 100 | 18.63 |
| 12:28 ET | 100 | 18.575 |
| 12:32 ET | 100 | 18.58 |
| 12:39 ET | 100 | 18.565 |
| 12:50 ET | 100 | 18.54 |
| 12:51 ET | 100 | 18.54 |
| 12:53 ET | 100 | 18.6 |
| 12:57 ET | 2200 | 18.63 |
| 01:00 ET | 1152 | 18.61 |
| 01:06 ET | 200 | 18.57 |
| 01:08 ET | 120 | 18.57 |
| 01:09 ET | 1673 | 18.62 |
| 01:11 ET | 100 | 18.57 |
| 01:13 ET | 4892 | 18.64 |
| 01:15 ET | 1986 | 18.68 |
| 01:20 ET | 100 | 18.59 |
| 01:26 ET | 600 | 18.51 |
| 01:31 ET | 100 | 18.5 |
| 01:36 ET | 200 | 18.455 |
| 01:38 ET | 980 | 18.56 |
| 01:40 ET | 200 | 18.5 |
| 01:42 ET | 100 | 18.495 |
| 01:44 ET | 100 | 18.52 |
| 01:45 ET | 100 | 18.495 |
| 01:47 ET | 911 | 18.57 |
| 01:49 ET | 200 | 18.615 |
| 01:51 ET | 100 | 18.68 |
| 01:54 ET | 100 | 18.625 |
| 01:56 ET | 2975 | 18.84 |
| 02:05 ET | 1570 | 18.95 |
| 02:07 ET | 100 | 18.95 |
| 02:09 ET | 1200 | 18.94 |
| 02:14 ET | 100 | 18.925 |
| 02:16 ET | 910 | 18.91 |
| 02:20 ET | 400 | 18.9 |
| 02:21 ET | 2140 | 18.94 |
| 02:23 ET | 1577 | 18.945 |
| 02:27 ET | 100 | 18.945 |
| 02:32 ET | 1233 | 18.92 |
| 02:34 ET | 200 | 18.95 |
Nov 1, 2024
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 5:26PM ET on Friday Nov 01, 2024 by Dow Jones
5:26PM ET on Friday Nov 01, 2024 by Dow Jones
Oct 28, 2024
NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November, from 4:30PM ET on Monday Oct 28, 2024 by Dow Jones
4:30PM ET on Monday Oct 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
NewAmsterdam Pharma Company NV | 1.6B | -7.2x | --- |
Bicycle Therapeutics PLC | 1.6B | -7.2x | --- |
Syndax Pharmaceuticals Inc | 1.6B | -5.7x | --- |
Celldex Therapeutics Inc | 1.7B | -9.1x | --- |
Tarsus Pharmaceuticals Inc | 1.8B | -10.3x | --- |
Rocket Pharmaceuticals Inc | 1.5B | -6.1x | --- |
Company Information
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
Contact Information
- Headquarters
- Gooimeer 2-35NAARDEN, Netherlands 1411 DC
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- William Lewis
- Chief Executive Officer, Executive Director
- Michael Davidson
- Interim Chief Financial Officer
- Louise Kooij
- Chief Operating Officer
- Douglas Kling
- Chief Scientific Officer, Non-Executive Director
- John Kastelein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.6B |
|---|---|
Revenue (TTM) | $7.4M |
Shares Outstanding | 90.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.00 |
EPS | $-2.64 |
Book Value | $3.50 |
P/E Ratio | -7.2x |
Price/Sales (TTM) | 218.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,792.90% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
